Zev Wainberg

  • Share
  • Print
  • PDF version

Awards as Co-PI

Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial of the novel first-in-class Polo-like Kinase 4 (PLK4) inhibitor, CFI-400945 in patients with advanced solid tumors